Upcoming Events
|
Save the Date!
SBRI's next Global Health 101 is
5:30-7:30 p.m., Thursday, June 11, in the Discovery Conference Room.
|
|
|
|
SBRI Expands TB Program
 Continuing its pattern of growth, SBRI has just topped 300 employees with the addition of another world-class principal investigator and expansion onto an additional floor of the South Lake Union building. Welcome, Dr. Grundner! As SBRI's 16th principal investigator, Christoph Grundner, Ph.D., is joining the Institute's tuberculosis research program, which focuses on the biology of the TB bacterium as a means to discover much needed new drugs for the disease. Grundner is the second principal investigator in SBRI's two-year-old tuberculosis research program, joining David Sherman, Ph.D., who heads the TB initiative at SBRI. New TB research facility: Grundner's arrival at SBRI coincides with SBRI's expansion onto the second floor of its South Lake Union building. This allows for growth in SBRI's malaria program, as well as its tuberculosis program, and provides space for a specialized laboratory for TB research, opening later this month. Read the related press release. |
$463,282 Raised at Passport Celebration
 More than 700 global health enthusiasts joined SBRI for its fifth annual Passport to Global Health Celebration, held April 23 at the Washington State Convention and Trade Center, and raised a total of $463,282 to accelerate SBRI's lifesaving research. During his keynote address, Dr. Paul Farmer urged the Seattle community to continue its support of infectious disease research. "We are on the
path to real progress in global health-building on successes," explained Farmer. "Still, there
are many people waiting for solutions. I am on the delivery end, but
we have nothing to offer unless we have the fruits of basic science." Read on, and watch Dr. Farmer's keynote address on UWTV.View photos from the event. |
Center Contributes to Swine Flu Solutions
Following the recent outbreak of H1N1 (swine flu), scientists at SBRI who are part of the Seattle Structural Genomics Center for Infectious Diseases (SSGCID) are focused on determining if there are potential new drug targets or methods of strengthening current drugs being used to combat the disease. According to SBRI Principal Investigator Peter Myler, Ph.D., who leads the SSGCID, he and his collaborators are using state-of-the-art technology to experimentally determine the three-dimensional structure of some of the proteins from the new strain of swine flu. Read on.
| |
|
|
|
|
|
